Electromedical Technologies and Nazarbayev University to
Commence Landmark Alzheimer's Disease Research Program
- The Stage I research program now includes
development of targeted Alzheimer's
Disease therapy using bioelectronics
- Experienced neuroscientist Dr.
Sholpan Askarova to lead neuromodulation
research program
- Key objective is identification of
electrical frequencies with a neuroprotection potency
- Novel approach could emerge as alternative
Alzheimer's
Disease therapy to current, ineffective
pharmaceuticals
- Global therapy market is huge, estimated to reach $13.3
billion in 2023
SCOTTSDALE, AZ -- July
29, 2021 -- InvestorsHub NewsWire -- Electromedical Technologies,
Inc. (OTCQB:
EMED)
(the "Company"), a pioneer in the development
and production
of bioelectronic
devices designed to relieve chronic, intractable and acute pains by
using frequencies and electro-modulation, is expanding its Stage I
research programs in collaboration with Nazarbayev University
to development an Alzheimer's
disease therapy by identifying electrical frequencies with a
neuroprotection potency. It is hoped that this novel
research program could lead to further non-invasive
bioelectronic therapy development
as an alternative to current pharmaceutical therapy which has
largely proven ineffective in treating this incurable, debilitating
disease. Published reports suggest 44
million people worldwide suffer from Alzheimer's Disease
or a related form
of dementia. Thus, the global Alzheimer's Disease
treatment market
is expected to reach $13.3 billion in 2023, according to
GlobalData.
Alzheimer's Disease
is a most common
form of the age-related neurodegenerative disorder causing loss of
memory, dramatic changes in character and behavior progressing to
inability to carry out normal daily life activities. The disease
pathology is linked to accumulation of a toxic beta-amyloid peptide
(Aß42) in brain tissues leading to a major cellular stress in brain
cells associated with mitochondrial dysfunction,
neuro-inflammation, and ultimately to a gradual death of neuronal
cells.
Matthew Wolfson, Founder and
CEO of Electromedical Technologies, comments, "So far, Alzheimer's
disease remains incurable because all pharmaceutical drug
development attempts to create the effective medicines have not
been successful. We must explore
alternative
therapies
for our
loved ones and
future generations. The various non-invasive
biophysical methods such as ultrasound, laser and electromagnetic fields
are actively pursued and shown promises in the recent decade. It is
our core interest to develop non-invasive neuromodulation effects
by identifying the effective electrical frequencies to
relieve Alzheimer's Disease
related stress on
neurons, to promote neuroprotection and, therefore, to extend a
neuronal survival with prolongation of brain functionality. We are
actively expanding our programs in this area and it is a major
focus of our research team led by Professor Dos D.
Sarbassov,
Professor of the Department of Biology, School of Sciences and
Humanities at Nazarbayev University."
Dr. Sarbassov is a prominent
expert in cell signaling, who received an intensive postdoctoral
research training at MIT's Whitehead Institute for Biomedical
Research and worked for many years as a Faculty Member of the
Molecular and Cellular Oncology Department at MD Anderson Cancer
Center. He joined Nazarbayev University in 2019 to contribute to a
scientific development of the country of his origin. In 2020, Dr.
Sarbassov became a Director of the National Laboratory Astana
(NLA), a leading research organization at Nazarbayev
University.
Dr. Dos Sarbassov commented,
"It is a great collaborative effort of academic
institutions combined with the industrial sector that is
instrumental for advancing development of a potent neuroprotective
therapy to alleviate the AD related brain pathology. It is a
challenging task and our research team is strengthened by
the
recent addition
of an experienced neuroscientist Dr. Sholpan Askarova to lead our neuromodulation
research program. It is an exciting time for us to set up the
groundbreaking research with a purpose to incite neuronal cells by
an extracellular electrical wave."
Dr. Sholpan Askarova is head of the Laboratory of
Bioengineering and Regenerative Medicine at NLA. Following her
research training in Cell and Tissue Biology at
al-Farabi Kazakh National University
(Almaty, Kazakhstan), she received a PhD degree in Bioengineering
in 2011 from the University of Missouri.
Dr. Askarova's
primary research
interests are the molecular and cellular mechanisms of
neurodegenerative diseases and aging by studying cell signaling
pathways and damaging effect of amyloid-beta-peptide implicated in
Alzheimer's disease. In addition, she has studied
the effects of a low energy
electromagnetic fields on brain cells, which dovetails with the AD
research program. Dr. Askarova has notably
published a
number of papers in this field.
"Oxidative stress induced by
accumulation of amyloid-beta peptide is one of the main mechanisms
leading to neuronal dysfunction in AD. Monitoring oxidative stress
in neuronal and astrocytic cells is our working platform in
identifying the potent electrical frequencies neutralizing the
damaging impact provoked by a stressful environment. This
exciting research project will be carried out by Dr. Andrey
Tsoy, a most experienced and
leading scientist in my laboratory," noted Dr. Sholpan Askarova.
Matthew Wolfson commented
further, "Bioelectronics
or
"electroceuticals"
is an exciting
emerging category of medicine. Our flagship
device, the Wellness Pro
Plus, has been helping thousands of
people suffering from
chronic
pain, live pain free and
have
a better quality
of life. Through our research
we are
excited for the possibilities
to one day
understand
the mechanisms of electrical
signaling on cells in an effort to
provide a solid
foundation in our development of effective novel therapies and
treatments of
inflammation, neurodegenerative disorders and opioid addiction
using
frequencies.
With
this research program and
the
parameters
we are
putting in
place, the Company and the University look forward to commencing
the IDE (Investigational Device Exemption) process leading to a
submission with the FDA."
About
Nazarbayev University:
Nazarbayev University (NU),
established on the initiative of the first President of the
Republic of Kazakhstan in 2010, is the country's flagship academic
institution with aspirations to become a global-level research
university. This is the first university in Kazakhstan which is
guided by the principles of autonomy and academic freedom. Located
in the capital of Kazakhstan, NU is a research university with
growing international renown combining education, research and
innovation on a state of the art 21st-century campus. NU scholars
conduct research in many fields, and seek to expand human knowledge
through innovation, analysis, and collaboration. Within ten years
since its inception, NU has become a leading research university in
Kazakhstan. NU research is supported by the government of the
Republic of Kazakhstan, local and international organizations, and
is carried out in the Schools, Research Centers and Institutes.
Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive
information on the NU research activities and profiles of faculty
and researchers.
About
Electromedical Technologies
Headquartered in
Scottsdale, Arizona, Electromedical
Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially
focused on the treatment of various chronic, acute, intractable,
and post-operative pain conditions. Through University collaboration
agreements, the Company is working to develop
a comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and effects on virus assembly
and immune responses, the Company's goal is
to reduce
pain and improve overall human wellbeing.
The Company's
current FDA cleared product
indications are for chronic acute post traumatic and
post-operative, intractable pain relief. For more information,
please
visit
www.electromedtech.com. Nonhuman preliminary studies
that we are planning to start in the
near
future and their
applications are not
related to our current product in any way and currently not cleared
in the US.
Safe Harbor
Statement
This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance or
guarantee that such expectations and assumptions will prove to have
been correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions, events
conditioned on stockholder or other approval, or otherwise as to
future events, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements
contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Hanover
International
Tel:
1.888.880.7888
email:
ir@electromedtech.com
https://electromedtech.com
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From Apr 2023 to Apr 2024